Flebogamma (Instituto Grifols SA)

Flebogamma (Instituto Grifols SA) - General Information

Mixture of IgG1 and other antibodies derived from human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. Flebogamma contains the IgG antibody specificities found in the general human population. IgG subclasses are fully represented in the following proportions: IgG1 is 70.3%, IgG2, 24.7%, IgG3, 3.1%, and IgG4,
1.9%

Pharmacology of Flebogamma (Instituto Grifols SA)

Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immune globulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.

Flebogamma (Instituto Grifols SA) for patients

Flebogamma (Instituto Grifols SA) Interactions

Flebogamma (Instituto Grifols SA) Contraindications

BayGam should not be given to persons with isolated immunoglobulin A (IgA) deficiency. Such persons have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA. ⁹

BayGam should not be administered to patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

Additional information about Flebogamma (Instituto Grifols SA)

Flebogamma (Instituto Grifols SA) Indication: For treatment of immunodeficiencies, thrombocytopenic purpura, Kawasaki disease, gammablobulinemia, leukemia, bone transplant
Mechanism Of Action: Antibodies prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Immune globulin
Synonyms: Ig alpha-2 chain C region
Drug Category: Anti-Infectives; Immunomodulatory Agents
Drug Type: Biotech; Approved; Investigational

Other Brand Names containing Immune globulin: Flebogamma (Instituto Grifols SA); Gamunex (Talecris Biotherapeutics);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: >20 hours (mammalian reticulocytes, in vitro).
Dosage Forms of Flebogamma (Instituto Grifols SA): Solution Intramuscular
Powder, for solution Intravenous
Solution Intravenous
Chemical IUPAC Name: Human antibodies
Chemical Formula: C6332H9826N1692O1980S42
Immune globulin on Wikipedia: Not Available
Organisms Affected: Humans and other mammals; Bacteria and protozoa; Various viruses